BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29432192)

  • 1. Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm.
    Di Gennaro A; Araújo AC; Busch A; Jin H; Wågsäter D; Vorkapic E; Caidahl K; Eriksson P; Samuelsson B; Maegdefessel L; Haeggström JZ
    Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1907-1912. PubMed ID: 29432192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cysteinyl-leukotrienes in abdominal aortic aneurysm.
    Araújo AC; Tang X; Haeggström JZ
    Prostaglandins Other Lipid Mediat; 2018 Nov; 139():24-28. PubMed ID: 30248405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Induces M2 Macrophage Polarization and Inhibits Murine Aortic Aneurysm Formation.
    Kawai Y; Narita Y; Yamawaki-Ogata A; Usui A; Komori K
    Biomed Res Int; 2019; 2019():9104680. PubMed ID: 31263710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
    Shimbori C; Shiota N; Okunishi H
    Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema.
    Ikeda G; Miyahara N; Koga H; Fuchimoto Y; Waseda K; Kurimoto E; Taniguchi A; Tanimoto Y; Kataoka M; Tanimoto M; Kanehiro A
    Am J Respir Cell Mol Biol; 2014 Jan; 50(1):18-29. PubMed ID: 23937413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Kinin B2 Receptor Signaling Controls Aortic Dilatation and Rupture in the Angiotensin II-Infused Apolipoprotein E-Deficient Mouse.
    Moran CS; Rush CM; Dougan T; Jose RJ; Biros E; Norman PE; Gera L; Golledge J
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):898-907. PubMed ID: 26966276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of cysteinyl leukotriene receptors in angiogenesis in rat thoracic aortic rings.
    Xu L; Zhang L; Liu L; Fang S; Lu Y; Wei E; Zhang W
    Pharmazie; 2010 Oct; 65(10):750-4. PubMed ID: 21105577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
    Said MM; Bosland MC
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
    Venugopal N; Acharya P; Zarei M; Talahalli RR
    Inflammopharmacology; 2019 Oct; 27(5):923-931. PubMed ID: 31309487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome.
    Gautier-Veyret E; Bäck M; Arnaud C; Belaïdi E; Tamisier R; Lévy P; Arnol N; Perrin M; Pépin JL; Stanke-Labesque F
    Pharmacol Res; 2018 Aug; 134():311-319. PubMed ID: 29920371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
    Yu GL; Wei EQ; Zhang SH; Xu HM; Chu LS; Zhang WP; Zhang Q; Chen Z; Mei RH; Zhao MH
    Pharmacology; 2005 Jan; 73(1):31-40. PubMed ID: 15452361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm.
    Di Gennaro A; Wågsäter D; Mäyränpää MI; Gabrielsen A; Swedenborg J; Hamsten A; Samuelsson B; Eriksson P; Haeggström JZ
    Proc Natl Acad Sci U S A; 2010 Dec; 107(49):21093-7. PubMed ID: 21078989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Montelukast modulates lung CysLT(1) receptor expression and eosinophilic inflammation in asthmatic mice.
    Zhang YJ; Zhang L; Wang SB; Shen HH; Wei EQ
    Acta Pharmacol Sin; 2004 Oct; 25(10):1341-6. PubMed ID: 15456537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
    Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
    Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model.
    Muz MH; Deveci F; Bulut Y; Ilhan N; Yekeler H; Turgut T
    Exp Mol Med; 2006 Apr; 38(2):109-18. PubMed ID: 16672764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist.
    Tuğtepe H; Sener G; Cetinel S; Velioğlu-Oğünç A; Yeğen BC
    Eur J Pharmacol; 2007 Feb; 557(1):69-75. PubMed ID: 17173892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1.
    Biagioli M; Carino A; Marchianò S; Roselli R; Di Giorgio C; Bordoni M; Fiorucci C; Sepe V; Conflitti P; Limongelli V; Distrutti E; Baldoni M; Zampella A; Fiorucci S
    Biochem Pharmacol; 2020 Jul; 177():113987. PubMed ID: 32330496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
    Lai J; Hu M; Wang H; Hu M; Long Y; Miao MX; Li JC; Wang XB; Kong LY; Hong H
    Neuropharmacology; 2014 Apr; 79():707-14. PubMed ID: 24456746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting the Th17/IL-17A-related inflammatory responses with digoxin confers protection against experimental abdominal aortic aneurysm.
    Wei Z; Wang Y; Zhang K; Liao Y; Ye P; Wu J; Wang Y; Li F; Yao Y; Zhou Y; Liu J
    Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2429-38. PubMed ID: 25234817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High serum thrombospondin-1 concentration is associated with slower abdominal aortic aneurysm growth and deficiency of thrombospondin-1 promotes angiotensin II induced aortic aneurysm in mice.
    Krishna SM; Seto SW; Jose R; Li J; Moxon J; Clancy P; Crossman DJ; Norman P; Emeto TI; Golledge J
    Clin Sci (Lond); 2017 Jun; 131(12):1261-1281. PubMed ID: 28364044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.